PharmaEssentia announced on the 2nd a capital investment of US$46 million (approx. NT$1.45 billion) to establish a subsidiary and manufacturing facility in Puerto Rico. This marks the launch of a "Taiwan-U.S. Dual Production Base" model.

• Strategic Rationale: CEO Ko-Chung Lin stated the plant will mitigate single-site production risks in Taiwan, enhance supply chain resilience, and leverage local tax incentives to reduce costs.
• Timeline: The facility is expected to secure regulatory certification and commence production by 2027.
• Market Context: The company’s lead product, Ropeg (a long-acting interferon), is approved in nearly 50 countries for Polycythemia Vera (PV). With the expected 2026 approval for Essential Thrombocythemia (ET) in the U.S., the Puerto Rico site—located in the "Carribean Bio-Valley" alongside giants like Pfizer and Amgen—is critical for meeting expanding U.S. demand.

Resource: 藥華藥砸14.5億赴波多黎各設廠 強化美國供應鏈